Emapalumab (anti-IFNγ)

目录号:A2041         批次号: A204103

打印

Emapalumab (anti-IFNγ)是一种针对IFNγ的单克隆抗体,是第一个全球批准用于治疗难治性原发性噬血性血细胞淋巴组织细胞增多症(HLH)的儿童和成人患者的治疗方法。

抗体信息

CAS号 1709815-23-5
配制 PBS Buffer, PH 7.4
推荐同型对照 Human IgG1
应用 Emapalumab (anti-IFNγ)
储存条件
(自收到货起)
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.
除菌 0.2 μM filtered
纯度 99%
蛋白浓度 9.24mg/ml
内毒素 <1EU/mg

Emapalumab (anti-IFNγ)在文献中得到引用

IFNγ regulates ferroptosis in KFs by inhibiting the expression of SPOCD1 through DNMT3A [ Cell Death Discov, 2025, 11(1):9] PubMed: 39820341
Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in Multiple Myeloma [ Blood Adv, 2024, bloodadvances.2023012522] PubMed: 39058976

禁止用于人体及治疗!